These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25945831)

  • 21. Synthesis and evaluation of γ-lactam analogs of PGE₂ as EP4 and EP2/EP4 agonists.
    Kambe T; Maruyama T; Nakai Y; Oida H; Maruyama T; Abe N; Nishiura A; Nakai H; Toda M
    Bioorg Med Chem; 2012 Jun; 20(11):3502-22. PubMed ID: 22546206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model.
    Coelingh Bennink HJ; Heegaard AM; Visser M; Holinka CF; Christiansen C
    Climacteric; 2008; 11 Suppl 1():2-14. PubMed ID: 18464016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation.
    Erez R; Ebner S; Attali B; Shabat D
    Bioorg Med Chem Lett; 2008 Jan; 18(2):816-20. PubMed ID: 18061452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biologic half-life of bisphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2009 Mar; 134(13):651-2. PubMed ID: 19294610
    [No Abstract]   [Full Text] [Related]  

  • 25. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.
    Hirabayashi H; Fujisaki J
    Clin Pharmacokinet; 2003; 42(15):1319-30. PubMed ID: 14674786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats.
    Lin JH; Chen IW; Duggan DE
    Drug Metab Dispos; 1992; 20(4):473-8. PubMed ID: 1356720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 28. Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits.
    Turek J; Ebetino FH; Lundy MW; Sun S; Kashemirov BA; McKenna CE; Gallant MA; Plotkin LI; Bellido T; Duan X; Triffitt JT; Russell RG; Burr DB; Allen MR
    Calcif Tissue Int; 2012 Mar; 90(3):202-10. PubMed ID: 22249525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?].
    Miki T; Saito S
    Clin Calcium; 2006 Jan; 16(1):167-74. PubMed ID: 16397368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite.
    Verron E; Gauthier O; Janvier P; Pilet P; Lesoeur J; Bujoli B; Guicheux J; Bouler JM
    Biomaterials; 2010 Oct; 31(30):7776-84. PubMed ID: 20643480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel prostaglandin analogs as potent and selective EP2/EP4 dual agonists.
    Kambe T; Maruyama T; Nakai Y; Yoshida H; Oida H; Maruyama T; Abe N; Nishiura A; Nakai H; Toda M
    Bioorg Med Chem; 2012 Apr; 20(7):2235-51. PubMed ID: 22386979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
    McClung M; Harris ST; Miller PD; Bauer DC; Davison KS; Dian L; Hanley DA; Kendler DL; Yuen CK; Lewiecki EM
    Am J Med; 2013 Jan; 126(1):13-20. PubMed ID: 23177553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Image assessment of the treatment effect on osteoporosis: bisphosphonates].
    Sone T
    Clin Calcium; 2011 Jul; 21(7):1041-6. PubMed ID: 21719985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of prostaglandin E2 receptor subtype 4 agonist and sulfasalazine in mouse colitis prevention and treatment.
    Jiang GL; Im WB; Donde Y; Wheeler LA
    J Pharmacol Exp Ther; 2010 Dec; 335(3):546-52. PubMed ID: 20833794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of basic fibroblast growth factor and a prostaglandin E2 receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats.
    Aguirre JI; Leal ME; Rivera MF; Vanegas SM; Jorgensen M; Wronski TJ
    J Bone Miner Res; 2007 Jun; 22(6):877-88. PubMed ID: 17352655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Self-sacrificial MOFs for ultra-long controlled release of bisphosphonate anti-osteoporotic drugs.
    Vassaki M; Papathanasiou KE; Hadjicharalambous C; Chandrinou D; Turhanen P; Choquesillo-Lazarte D; Demadis KD
    Chem Commun (Camb); 2020 May; 56(38):5166-5169. PubMed ID: 32255461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats.
    Cameron KO; Lefker BA; Chu-Moyer MY; Crawford DT; Jardine PD; DeNinno SL; Gilbert S; Grasser WA; Ke H; Lu B; Owen TA; Paralkar VM; Qi H; Scott DO; Thompson DD; Tjoa CM; Zawistoski MP
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1799-802. PubMed ID: 16442794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading.
    Hagino H; Kuraoka M; Kameyama Y; Okano T; Teshima R
    Bone; 2005 Mar; 36(3):444-53. PubMed ID: 15777678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone affinity of a bisphosphonate-conjugated protein in vivo.
    Uludag H; Gao T; Wohl GR; Kantoci D; Zernicke RF
    Biotechnol Prog; 2000; 16(6):1115-8. PubMed ID: 11101342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.